ClinicalTrials.gg

Program

enrupatinib

Also written as “EI-1071” and “EI-1071 tablet, oral”.

Its studies are mostly in Lymphoma, Follicular, led by Elixiron Immunotherapeutics.

Furthest: phase 2, since Dec 12, 20243 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Elixiron Immunotherapeutics31 open or runningphase 2since Dec 12, 2024Jan 16, 2020Aug 2027phase 1 · NCT07903337

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 16, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04238364 · 58 enrolled · United States
  2. Dec 12, 2024Phase 2 study in Lymphoma, FollicularNCT06745583 · 7 enrolled · Taiwan
  3. Sep 29, 2026Phase 1 study in Food Effect in Healthy VolunteersNCT07903337 · 25 planned · Taiwan

Ahead

  1. Aug 2027Primary completion: phase 1 study in Food Effect in Healthy VolunteersNCT07903337

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07903337Food Effect in Healthy Volunteers · Taiwan1Not yet recruitingAug 202725
NCT06745583Lymphoma, Follicular · Taiwan2CompletedMar 6, 20267
NCT04238364Healthy Volunteers · United States1CompletedDec 16, 202158

How it is read

Names in the registry

  • “EI-1071”, 2 entries
  • “EI-1071 tablet, oral”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.